SEC Form 5 
FORM 5	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0362	
Estimated average burden	
hours per response:	1.0	

	
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			
	Form 3 Holdings Reported.			
	Form 4 Transactions Reported.			
1. Name and Address of Reporting Person*
Aliabadi Paymon	

(Last)	(First)	(Middle)	
10 S. DEARBORN STREET	
54TH FLOOR	

(Street) 
CHICAGO	IL	60603	

(City)	(State)	(Zip)	
	2. Issuer Name and Ticker or Trading Symbol 
EXELON Corp [ EXC ] 	5. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
	Director		10% Owner	
X	Officer (give title below)		Other (specify below)	
EVP, Chief Enterprise Risk Ofr	
		
	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
12/31/2018 		
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) 
X	Form filed by One Reporting Person	
	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1. Title of Security (Instr. 3) 	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) 	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) 	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	7. Nature of Indirect Beneficial Ownership (Instr. 4) 		
				Amount	(A) or (D)	Price					
Common Stock							50,539	D			
Common Stock (ESPP Shares)							365(1) 	D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 3) 	2. Conversion or Exercise Price of Derivative Security 	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 	8. Price of Derivative Security (Instr. 5) 	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	11. Nature of Indirect Beneficial Ownership (Instr. 4) 	
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Unit Awards 2016	$0 						(2) 	(2) 	Common Stock	8,024		8,024(3) 	D		
Restricted Stock Unit Awards 2017	$0 						(2) 	(2) 	Common Stock	11,996		11,996(4) 	D		
Restricted Stock Unit Awards 2018	$0 						(2) 	(2) 	Common Stock	15,890		15,890(5) 	D		
Explanation of Responses:	
1. Shares acquired through Exelon's Section 423 tax-qualified Employee Stock Purchase Plan.	
2. Previously awarded restricted stock units (RSUs) granted pursuant to the Exelon Long Term Incentive Plan. RSUs are granted annually at the Compensation and Leadership Development committee's first meeting in January or February and vest in 1/3 increments on the date of the committee's first annual meeting in the first, second and third years after the award was granted. Award balances accrue addtional RSUs through quarterly dividend reinvestment that vest on the same schedule as the underlying award.	
3. Balance includes 259 shares acquired through quarterly dividend reinvestment during 2018.	
4. Balance includes 387 shares acquired through quarterly dividend reinvestment during 2018.	
5. Balance includes 512 shares acquired through quarterly dividend reinvestment during 2018.	
Remarks:	
	
	Katherine A. Smith, Attorney-in-Fact for Paymon Aliabadi	01/29/2019	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.	
EXELON CORPORATION
SECTION 16 REPORTING POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints
each of Carter C. Culver, Katherine A. Smith, Brian Buck and Tom Boin,
signing singly, the undersigned's true and lawful attorney-in-fact to:

(1)     execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and or director of Exelon Corporation ("Exelon"), all
reports to be filed by the undersigned pursuant to Section 16(a) of the
Securities Exchange Act of 1934 and the rules promulgated thereunder (including
EDGAR Form ID, Forms 3, 4, and 5 and any successor forms) (the "Section 16
Reports");

(2)     do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to complete and execute any such Section 16
Report, complete and execute any amendment or amendments thereto, and timely
file such report with the United States Securities and Exchange Commission and
any stock exchange or similar authority; and

(3)     take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is Exelon assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Section 16 Reports with respect to the
undersigned's holdings of and transactions in securities issued by Exelon,
unlessearlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 14th day of January 2019.

Signature: /s/ Paymon Aliabadi

Print Name:  Paymon Aliabadi